Noviga Research

Noviga Research is a Swedish biotechnology company focused on developing innovative oncology treatments by targeting DNA repair mechanisms in cancer cells. Founded by Professor Thomas Helleday, a pioneer in the field of synthetic lethality, the company leverages deep expertise in DNA damage response (DDR) to create highly selective therapies. Their lead program, NOV202, is a potent small molecule inhibitor of DNA polymerase theta (POLQ), designed to treat patients with homologous recombination-deficient tumors, such as those with BRCA1 or BRCA2 mutations. By exploiting the specific genetic vulnerabilities of cancer cells, Noviga aims to provide effective alternatives to traditional chemotherapy with significantly reduced side effects. The company operates primarily out of the Karolinska Institutet Science Park, maintaining strong ties to academic research and clinical expertise.